OBJECTIVES: To assess the clinical characteristics of patients with RA who received biologic monotherapy (“Mono”) or biologic-containing combination therapy (“Combo”) in Europe. METHODS:  A multi-country, multi-center medical chart review study of patients with RA was conducted in Q42012 among physicians in hospitals and private practices to collect de-identified data on patients who were recently treated with a biologic as part of usual care in France/Germany/Italy/Spain/UK. Physicians were screened for duration of practice (3-30yrs) and patient volume (≥2 RA biologic patients/week) and recruited from a large panel to be geographically representative in each country. Eligible patient charts (≥5) were randomly selected from among the patients visiting each center/practice during the screening period. Physicians abstracted date of diagnosis, treatment patterns/dynamics, and symptomatology/disease status. Mono and Combo patients were compared used descriptive statistics. RESULTS: CONCLUSIONS: In this cohort of RA patients in Europe, the majority of patients on monotherapy and combination therapy had mild disease per physician judgment and were on first-line biologic therapy. Lab measures and joint counts indicated only slightly higher disease burden among combination therapy patients. The impact of specific biologic treatments on observed patterns and the need for therapeutic sequencing may warrant further research.